In the present study, we describe the identification of ZJ01 as a new Keap1–Nrf2 PPI inhibitor and further investigate its in vitro and in vivo cytoprotective effects on LPS-induced cardiomyopathy. Here, NFE2L2 is linked to cardiomyopathy.